Acumen Pharmaceuticals, Inc.

#ICYMI: Our R&D Day on October 2nd featured insights into our strategic vision and the development of sabirnetug for Alzheimer’s disease. If you missed it live, don’t worry—you can still catch the webcast! ???? ?? https://lnkd.in/gT8v9dH8 #AlzheimersResearch #Innovation

This year, we are supporting the Alzheimer's Association? in their "Walk to End Alzheimer’s" campaign. ??This past weekend Acumen team members hit the pavement in Bloomington, IN. Kudos to Janice Hitchcock, Ph.D. & Amy Hutchinson along with their families and friends for their commitment to the cause! #EndAlz #TeamAcumen #WalkToEndAlzheimers #Walk2ENDALZ

This year, we are supporting the Alzheimer's Association? in their "Walk to End Alzheimer’s" campaign. ??This past weekend Acumen team members hit the pavement in Indianapolis, IN. Kudos to Eric Siemers MD & Julie Bockenstette for their commitment to the cause! #EndAlz #TeamAcumen #WalkToEndAlzheimers #Walk2ENDALZ

We are thrilled to extend our collaboration with Lonza to enable the potential future commercial launch of?sabirnetug, our next-generation investigational treatment for Alzheimer’s disease that targets toxic soluble amyloid beta oligomers. Lonza will now manufacture cGMP drug product at their state-of-the-art facility in Visp, Switzerland for ongoing and future clinical phases and support our potential commercial launch of sabirnetug. They will also provide quality control and stability testing. Learn more about our collaboration in today’s press release: https://lnkd.in/gGSTffYy #AlzheimersDisease #ClinicalTrials #Lonza #AcumenPharmaceuticals

Today Acumen announced that we will host a virtual R&D Day on Wednesday, Oct. 2 at 10:00 a.m. ET. The webcast will highlight our strategic vision, and focus on the mechanistic rationale, pre-clinical and clinical data that support further development of sabirnetug as a treatment for early AD. Click the link to register: https://lnkd.in/gimPBNbD

This year, we are supporting the Alzheimer's Association? in their "Walk to End Alzheimer’s" campaign. ??This past weekend Acumen team members hit the pavement in Chicago, IL and Minneapolis, MN. Kudos to Maddelyn Hyland, MPH & Robyn Moxon along with their families and friends for their commitment to the cause! #EndAlz #TeamAcumen #WalkToEndAlzheimers #Walk2ENDALZ

Tomorrow September 21st is World Alzheimer’s Day, a pivotal point during World Alzheimer’s Month championed by Alzheimer's Disease International. Their newly released "World Alzheimer’s Report" highlights global survey responses, showcasing the urgent need for increased advocacy, education, and support for those impacted by Alzheimer’s disease. Together, we can break the stigma, raise awareness, and improve the lives of millions of people worldwide. Let’s unite to champion better care, understanding, and research for a future without Alzheimer’s. Link to the report: https://lnkd.in/gmNHrZN8 #TimeToActOnDementia #TimeToActOnAlzheimers #WorldAlzMonth

Exciting News!?Our President & Chief Development Officer Jim Doherty sat down with Outsourced Pharma to discuss Acumen’s partnership with Lonza for manufacturing sabirnetug (ACU193), leveraging their expertise in antibody production. This collaboration highlights the importance of strategic CDMO partnerships in advancing innovative treatments. Read the full interview: https://lnkd.in/gJUymj6w #Alzheimers #ALZ?

Our team recently gathered for a productive and energetic meeting where we took a moment to acknowledge the incredible progress and hard work everyone has contributed to the ALTITUDE-AD study. By working together as one team, we continue to make significant strides toward our shared goals.

There are estimated to be 55 million people living with dementia globally, however many people do so without a formal diagnosis. An accurate diagnosis of dementia can help improve access to treatment, care and support to enable those living with a diagnosis to live independently for as long as possible. September is World Alzheimer's Month, and this year Alzheimer's Disease International's theme is: “Time to Act on Dementia”, awareness raising campaigns can help address misinformation and stigma surrounding the condition and promote risk reduction.?The time to act is now. Click the link to learn more about the campaign: https://lnkd.in/eGsXmt4K #TimeToActOnDementia #TimeToActOnAlzheimers #WorldAlzMonth